Engaging Expectant Parents to Receive Tdap Vaccination

School of Medicine, Duke University, Durham, North Carolina.
American Journal of Perinatology (Impact Factor: 1.91). 08/2013; 31(5). DOI: 10.1055/s-0033-1352483
Source: PubMed


To assess the acceptability of a Tdap vaccination program for partners of pregnant women.

Study design:
Pregnant women and their partners were enrolled in a prospective acceptability study. For partners absent during the initial encounter, an introductory letter inviting the partner to participate was sent home. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) was offered to vaccine-eligible partners while vaccine-eligible pregnant women were offered Tdap immediately postpartum, as per national recommendations at the time the study was conducted. Tdap acceptance was defined as vaccination during study participation.

A total of 69 pregnant women and 63 partners were enrolled. Excluding the 19 partners reporting prior receipt, 61.4% of partners (27/44) accepted Tdap during the study. Those who enrolled following the introductory letter were more likely to accept Tdap than those enrolled at the initial encounter (84 vs. 44%, p = 0.005). Excluding the 29 pregnant women reporting prior receipt, 65% (26/40) received Tdap postpartum. Demographic factors and vaccine beliefs were not associated with Tdap acceptance.

Tdap vaccination for partners of pregnant women during prenatal care is acceptable. Large-scale implementation would require substantial interest and willingness of obstetrician-gynecologists to administer Tdap not only to pregnant women but also to their partners. Such a program would provide improved "cocooning" of vulnerable infants against pertussis.

1 Follower
7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The rising incidence of whooping cough, a highly contagious infection caused by Bordetella pertussis, is particularly significant for young infants who have the highest risk for morbidity and mortality. The pertussis resurgence has led to a shift in primary prevention relying on childhood vaccination to a cocooning strategy, that is, vaccination of close contacts of newborn infants (new mothers, fathers, grandparents, siblings, caretakers, etc.), thereby reducing pertussis exposure. Immunization of women during pregnancy rather than during the immediate postpartum period (the initial cocooning recommendation) appears to be a better approach by directly providing protection through transplacental transfer of maternal vaccine-induced antibodies. This article describes neonatal pertussis, cocooning as a means of reducing neonatal exposure to pertussis and maternal immunization as a means of protecting young infants against pertussis infection.
    Expert Review of Vaccines 07/2014; 13(9):1-8. DOI:10.1586/14760584.2014.944509 · 4.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the fact that universal immunization against pertussis led to a dramatic decrease in the incidence and mortality in high-income countries, it has left a window of vulnerability for newborns. Although specific guidelines concerning management of neonatal whooping cough have not yet been developed, the present review summarizes the main available recommendations on diagnostic work-up and treatment of neonatal pertussis. Additionally, new prevention strategies are explored, including the use of an additional booster dose of vaccine to adolescents and adults, vaccination of healthcare workers, immunization of household contacts and caregivers (cocooning strategy), vaccination of pregnant women and, finally, neonatal immunization with novel vaccines. These strategies are analyzed and discussed in terms of efficacy, safety and cost-effectiveness.
    Expert Review of Anti-infective Therapy 11/2014; 12(12):1-17. DOI:10.1586/14787210.2014.979156 · 2.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the United States, eradication and reduction of vaccine-preventable diseases through immunization has directly increased life expectancy by reducing mortality. Although immunization is a public priority, vaccine coverage among adult Americans is inadequate. The Institute of Medicine, the Community Preventive Services Task Force, and other public health entities have called for the development of innovative programs to incorporate adult vaccination into routine clinical practice. Obstetrician-gynecologists are well suited to serve as vaccinators of women in general and more specifically pregnant women. Pregnant women are at risk for vaccine-preventable disease-related morbidity and mortality and adverse pregnancy outcomes, including congenital anomalies, spontaneous abortion, preterm birth, and low birth weight. In addition to providing direct maternal benefit, vaccination during pregnancy likely provides direct fetal and neonatal benefit through passive immunity (transplacental transfer of maternal vaccine-induced antibodies). This article reviews: 1) types of vaccines; 2) vaccines specifically recommended during pregnancy and postpartum; 3) vaccines recommended during pregnancy and postpartum based on risk factors and special circumstances; 4) vaccines currently under research and development for licensure for maternal-fetal immunization; and 5) barriers to maternal immunization and available patient and health care provider resources.
    Obstetrics and Gynecology 01/2015; 125(1):212-26. DOI:10.1097/AOG.0000000000000581 · 5.18 Impact Factor